Across TCGA pan-cancer cohorts, SRA1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SRA1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SRA1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRA1 expression acts as an unfavorable survival marker.

STAD, SKCM, and LIHC are the cancer types where SRA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
SKCM	DFS	Median	All	0.134	0.730	<.001	25	view →
LIHC	DFS	Median	All	0.092	0.543	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SRA1 tumor-vs-normal RNA expression · all SRA1 data types